EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a metaanalysis
Journal of Hematology & Oncology, 08/17/2012
Evidence Based Medicine
Yang ZY et al. – Although increased Epidermal growth factor receptor gene copy number (EGFR GCN) is generally associated with a better outcome of anti–EGFR monoclonal antibodies (MAbs) treatment, especially among patients with wild–type KRAS, the clinical utility of this biomarker for selecting recipients of anti–EGFR MAbs would be severely limited by the heterogeneous scoring system and the poor reproducibility of EGFR GCN enumeration due to technical reasons.
